Prosecution Insights
Last updated: November 12, 2026
Application No. 19/059,532

PRESCRIPTION DISPENSING SYSTEM

Non-Final OA §102§103§DOUBLEPATENT
Filed
Feb 21, 2025
Priority
Jul 01, 2019 — continuation of 11/200,979 +2 more
Examiner
WAGGONER, TIMOTHY R
Art Unit
3655
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Pharmabot LLC
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
79%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
1003 granted / 1399 resolved
+19.7% vs TC avg
Moderate +7% lift
Without
With
+7.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
40 currently pending
Career history
1440
Total Applications
across all art units

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,249,411. Although the claims at issue are not identical, they are not patentably distinct from each other because the present claims are a mere broadening of the previously allowed claims with some additional inherent steps claimed with regard to processing a prescription. The subject matter of claim 1 is disclosed in claim 1 of US 12,249,411. The subject matter of claim 2 is disclosed in claim 2 of US 12,249,411. The subject matter of claim 3 is disclosed in claim 3 of US 12,249,411. The subject matter of claim 4 is disclosed in claim 4 of US 12,249,411. The subject matter of claim 5 is disclosed in claim 5 of US 12,249,411. The subject matter of claim 6 is disclosed in claim 6 of US 12,249,411. The subject matter of claim 7 is disclosed in claim 7 of US 12,249,411. The subject matter of claim 8 is disclosed in claim 8 of US 12,249,411. The subject matter of claim 9 is disclosed in claim 9 of US 12,249,411. The subject matter of claim 10 is disclosed in claim 10 of US 12,249,411. The subject matter of claim 11 is disclosed in claim 11 of US 12,249,411. The subject matter of claim 12 is disclosed in claim 12 of US 12,249,411. The subject matter of claim 13 is disclosed in claim 14 of US 12,249,411. The subject matter of claim 14 is disclosed in claim 15 of US 12,249,411. The subject matter of claim 15 is disclosed in claims 17 and 18 of US 12,249,411. The subject matter of claim 16 is disclosed in claim 16 of US 12,249,411. The subject matter of claim 17 is disclosed in claim 17 of US 12,249,411. The subject matter of claim 18 is disclosed in claim 18 of US 12,249,411. The subject matter of claim 19 is disclosed in claim 19 of US 12,249,411. The subject matter of claim 20 is disclosed in claim 20 of US 12,249,411. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-2 and 11-15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Reese US 6,711,460. Reese discloses a pharmacy automation system comprising: (Re claim 1) “receive a prescription from a database, wherein the prescription comprises information of a prescribed medication” (510 figure 14, col 13-14 lines 50-3). “create a medication dispensing order based on the prescription” (530 figure 14, col 13-14 lines 50-3). “create a pick task for the medication dispensing order” (col 13-14 lines 50-3). “verify authenticity of one of a patient and a proxy” (520 figure 14). “notify in-network automatons to initiate the pick task” (‘robot’, col 13-14 lines 50-3). “retrieve the prescribed medication, using a robot, from a storage when the prescribed medication is available in a pharmacy” (‘drug retrieval robot’, col 13-14 lines 50-3). “fill a container with the prescribed medication” (col 17 lines 48-67). “verify authenticity of one of the patient and the proxy upon arrival to pick up the prescribed medication” (col 7 lines 20-24). “retrieve the container and hand over the container with the prescribed medication to one of the patient and the proxy” (col 7 lines 40-56). (Re claim 2) “the prescription is in a form of one of an audio and a digital recording” (col 5 lines 13-23). (Re claim 11). “the robot, verifying the authenticity of one of the patient and the proxy, is operable to check and approve an identification of one of the patient and the proxy” (col 7 lines 20-24). (Re claim 12) “the identification is in a form of biometric data and/or a photograph” (col 7 lines 20-24). (Re claim 13) “wherein the robot fills the container with a request amount of the prescribed medication as per the prescription” (col 10 lines 39-65). (Re claim 14) “the robot is operable to retrieve a lid and seal the container upon filling the container with the prescribed medication” (col 18 lines 36-44). (Re claim 15) “the robot is directed by a pharmacist from a remote location” (abstract). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 3 is/are rejected under 35 U.S.C. 103 as being unpatentable over Reese in view of Yered US 2006/0116905. Reese discloses the system as rejected above and a card reader to enter prescription information (col 7 lines 8-24) and the use of smart cards with IP addresses to transmit information regarding the prescription (col 8 lines 20-28). Reese does not disclose the prescription is in a form of an internet protocol (IP) address. Yered teaches that the prescription is in a form of an internet protocol (IP) address (para 0116). It would have been obvious to one skilled in the art to modify the system of Reese to include that the prescription is in a form of an internet protocol (IP) address because it provides further identifiable information for the customer. Claim(s) 4 is/are rejected under 35 U.S.C. 103 as being unpatentable over Reese in view of Haider et al. US 2008/0147518. Reese disclose the system as rejected above and working with multiple different pharmacies (abstract). Reese does not disclose that if the prescribed medication is not available in the pharmacy, the robot is configured to order a drug from a nearest pharmacy in network. Haider teaches that if the prescribed medication is not available in the pharmacy, the robot is configured to order a drug from a nearest pharmacy in network (abstract, para 0019). It would have been obvious to one skilled in the art to modify the system of Reese to include that if the prescribed medication is not available in the pharmacy, the robot is configured to order a drug from a nearest pharmacy in network because it allows the patient to get their medication as soon as possible. Claim(s) 5-10 and 16-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Reese in view of Vu et al. US 2007/0192910. Reese discloses the system as rejected above. Reese does not disclose that the robot comprises a hardware device and a software to perform the internal mapping, wherein the internal mapping is a simultaneous localization and mapping (SLAM). Vu teaches that the robot comprises a hardware device and a software to perform the internal mapping, wherein the internal mapping is a simultaneous localization and mapping (SLAM) (abstract, para 0105, 0237). It would have been obvious to one skilled in the art to modify Reese to include that the robot comprises a hardware device and a software to perform the internal mapping, wherein the internal mapping is a simultaneous localization and mapping because it allows for greater access to areas for both delivery and retrieval. (Re claim 6) “the robot determines the prescribed medication from the prescription” (col 14 lines 45-57). (Re claim 7) “the prescription is in a form of a prescription note or a medical card comprising a built-in memory chip containing at least information regarding the prescribed medication” (col 8 lines 43-57). (Re claim 8) “the robot is further configured to upload an information of the patient and/or the proxy to a doctor directly or an intermediary, the intermediary comprising an online database containing a list of doctors or a cloud network” (156, 144 figure 1,2, col 20 lines 40-52). (Re claim 9) Reese does not disclose that the hardware device comprises a rotary encoder and a laser. Vu teaches that the hardware device comprises a rotary encoder and a laser (para 0051, 0162). It would have been obvious to one skilled in the art to modify the system of Reese to include that the hardware device comprises a rotary encoder and a laser because it helps with navigation and avoiding collisions. (Re claim 10) “the software comprises a robot operating system” (abstract). (Re claim 16) Reese does not disclose that the robot is further operable to track a current location of the patient. Vu teaches that the robot is further operable to track a current location of the patient (para 0253). It would have been obvious to one skilled in the art to modify the system of Reese to include that the robot is further operable to track a current location of the patient because it allows for the robot to contact the patient faster. (Re claim 17) Reese does not disclose that the robot is further operable to maneuver to the current location of the patient. Vu teaches that the robot is further operable to maneuver to the current location of the patient. (abstract, claim 1). It would have been obvious to one skilled in the art to modify the system of Reese to include that the robot is further operable to maneuver to the current location of the patient because it allows direct delivery to the patient especially if the patient has mobility issues. (Re claim 18) Reese does not disclose that the robot is further operable to deliver the prescribed medication at the current location of the patient. Vu teaches that the robot is further operable to deliver the prescribed medication at the current location of the patient (para 0271). It would have been obvious to one skilled in the art to modify the system of Reese to include that the robot is further operable to deliver the prescribed medication at the current location of the patient because it allows direct delivery to the patient especially if the patient has mobility issues. (Re claim 19,20) Reese does not disclose that the robot is further operable to communicate a schedule electronically to the patient in advance of time at which a delivery is to be made, wherein the schedule comprises at least a time and a location for a delivery of the prescribed medication and the robot is further operable to deliver the prescribed medication as per the schedule. Vu teaches that the robot is further operable to communicate a schedule electronically to the patient in advance of time at which a delivery is to be made, wherein the schedule comprises at least a time and a location for a delivery of the prescribed medication and the robot is further operable to deliver the prescribed medication as per the schedule (figure 11A, 11B). It would have been obvious to one skilled in the art to modify the system of Reese to include hat the robot is further operable to communicate a schedule electronically to the patient in advance of time at which a delivery is to be made, wherein the schedule comprises at least a time and a location for a delivery of the prescribed medication and the robot is further operable to deliver the prescribed medication as per the schedule because it helps to maintain compliance with prescription medications. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R WAGGONER whose telephone number is (571)272-8204. The examiner can normally be reached Mon-Thurs 5am-330pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jacob Scott can be reached at 571-270-3415. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. TIMOTHY R. WAGGONER Primary Examiner Art Unit 3655 B /TIMOTHY R WAGGONER/ Primary Examiner, Art Unit 3655
Read full office action

Prosecution Timeline

Feb 21, 2025
Application Filed
Oct 08, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790122
WAREHOUSING SYSTEM, CONTROL METHOD, ELECTRONIC DEVICE, AND STORAGE MEDIUM
1y 11m to grant Granted Nov 10, 2026
Patent 12774161
SYSTEM AND METHOD FOR PUBLIC AND PRIVATE WAREHOUSES MANAGEMENT WITH AUTOMATED EQUIPMENT
2y 4m to grant Granted Oct 27, 2026
Patent 12767450
TRACK SENSOR ARRANGEMENT
2y 1m to grant Granted Oct 20, 2026
Patent 12759863
ANOMALY DETECTION DURING FUEL DISPENSING OPERATIONS
4y 2m to grant Granted Oct 13, 2026
Patent 12763185
PRODUCT ORDER DOSING FILLER SYSTEMS AND RELATED METHODS
2y 11m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
79%
With Interview (+7.3%)
Low
PTA Risk
Based on 1399 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month